Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional)
The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for Substance Use Disorders (SUD).
The COA development plan is expected to progress into the FDA drug development tool qualification program.
This notice of funding opportunity (NOFO) utilizes the UG3/UH3Phased Innovation Awards Cooperative Agreement grant mechanism that includes two phases.
The applications responding to this NOFO should contain a COA development plan that will cover both UG3 and UH3 phases.
In the first 2-year UG3 phasethe project must have a set of operational milestones to be completed by the end of this period.
Once NIDA program has evaluated the progress of the UG3 phase and determined that the UG3 phase has been successfully completed, it transitions to the UH3 phase to be funded for three additional years.The goal of this NOFO is to expand the armamentarium of COA that are FDA qualified as drug development tool (DDT) in the context of use (COI) of a SUD.
Achieving this goal will greatly facilitate the development of treatments for SUDs.
This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.
Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.
Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
The COA development plan is expected to progress into the FDA drug development tool qualification program.
This notice of funding opportunity (NOFO) utilizes the UG3/UH3Phased Innovation Awards Cooperative Agreement grant mechanism that includes two phases.
The applications responding to this NOFO should contain a COA development plan that will cover both UG3 and UH3 phases.
In the first 2-year UG3 phasethe project must have a set of operational milestones to be completed by the end of this period.
Once NIDA program has evaluated the progress of the UG3 phase and determined that the UG3 phase has been successfully completed, it transitions to the UH3 phase to be funded for three additional years.The goal of this NOFO is to expand the armamentarium of COA that are FDA qualified as drug development tool (DDT) in the context of use (COI) of a SUD.
Achieving this goal will greatly facilitate the development of treatments for SUDs.
This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.
Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.
Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $20,000,000
Office: National Institutes of Health
Estimated Funding: $20,000,000
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-028.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U. S. Territory or Possession.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-028.html
Contact:
Agency Email Description:
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Agency Email:
Date Posted:
2023-12-18
Application Due Date:
Archive Date:
2024-08-14
Social Entrepreneurship
Spotlight
Partnerships in Social Enterprises Can Increase Social Impact
Chief executive of HCT, Dai Powell, shares the experiences and practical lessons he learned along the way when teaming up with Ealing Community Transport to deliver site transport during the Olympic Park construction.
Learn How to Identify and Avoid Grant Scams
